Miguel
Alcoceba Sánchez
Investigador desde 2011
Hospital Miguel Servet
Zaragoza, EspañaPublicaciones en colaboración con investigadores/as de Hospital Miguel Servet (12)
2021
-
6q deletion in Waldenström macroglobulinaemia negatively affects time to transformation and survival
British Journal of Haematology, Vol. 192, Núm. 5, pp. 843-852
-
Genomic mutation profile in progressive chronic lymphocytic leukemia patients prior to first-line chemoimmunotherapy with FCR and rituximab maintenance (REM)
PLoS ONE, Vol. 16, Núm. 9 September
2019
-
Life expectancy of follicular lymphoma patients in complete response at 30 months is similar to that of the Spanish general population
British Journal of Haematology, Vol. 185, Núm. 3, pp. 480-491
2017
-
Risk of, and survival following, histological transformation in follicular lymphoma in the rituximab era. A retrospective multicentre study by the Spanish GELTAMO group
British Journal of Haematology, Vol. 178, Núm. 5, pp. 699-708
2015
2013
-
MYD88 L265P is a marker highly characteristic of, but not restricted to, Waldenström's macroglobulinemia
Leukemia, Vol. 27, Núm. 8, pp. 1722-1728
2012
-
Prognostic significance of FLT3 mutational status and expression levels in MLL-AF4 and MLL-germline acute lymphoblastic leukemia
Leukemia, Vol. 26, Núm. 11, pp. 2360-2366
2010
-
BAALC is an important predictor of refractoriness to chemotherapy and poor survival in intermediate-risk acute myeloid leukemia (AML)
Annals of Hematology, Vol. 89, Núm. 5, pp. 453-458
-
Long FLT3 internal tandem duplications and reduced PML-RARα expression at diagnosis characterize a high-risk subgroup of acute promyelocytic leukemia patients
Haematologica, Vol. 95, Núm. 5, pp. 745-751
2009
-
High FOXO3a expression is associated with a poorer prognosis in AML with normal cytogenetics
Leukemia Research, Vol. 33, Núm. 12, pp. 1706-1709
-
Molecular stratification model for prognosis in cytogenetically normal acute myeloid leukemia
Blood, Vol. 114, Núm. 1, pp. 148-152
2008
-
The relevance of preferentially expressed antigen of melanoma (PRAME) as a marker of disease activity and prognosis in acute promyelocytic leukemia
Haematologica, Vol. 93, Núm. 12, pp. 1797-1805